Alkermes expands Phase 1 trial of ALKS 4230 in combination with KEYTRUDA for advanced solid tumors

Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety and anti-tumor activity of its immuno-oncology drug ... Read More